trial

NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

NCTId NCT07105098
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 284 (estimated)
Sponsored by Neurocrine Biosciences
Primary completion 2027-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
284 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2025-08-11
Primary completion
2027-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
NBI-1117568

Sponsors

Neurocrine BiosciencesLead Sponsor

Investigators

1
Clinical Development LeadStudy Director

Sites

15 total
Culver City, United StatesGarden Grove, United StatesRiverside, United StatesAtlanta, United StatesNorth Canton, United StatesSliven, BulgariaVeliko Tarnovo, BulgariaVratsa, BulgariaGyőr, HungaryBrasov, RomaniaBrasov, RomaniaBucharest, Romania

Linked catalysts

1
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph — primary completion2027-11

Facts & assertions

4 sourced
Enrollment
284
Phase
PHASE3
Primary Completion Date
2027-11
Status
RECRUITING
relationships
The graph out of here
drug
NBI-1117568
drug
lead_sponsor
Neurocrine Biosciences
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Clinical Development Lead
person